COMPLETE Trial
•
2 likes•994 views
The document discusses the COMPLETE Trial, a clinical trial conducted across 140 centers in 31 countries. It studied the guidelines for managing dyslipidemias and reported on the baseline characteristics of participants as well as procedural details. Secondary outcomes and safety results were also examined. Subgroup analyses from the trial are mentioned.
Report
Share
Report
Share
Recommended
PRAMI clinical trial (for STEMI intervention)
The PRAMI trial was a randomized controlled trial that compared preventive percutaneous coronary intervention (PCI) to PCI limited to the infarct artery in patients with ST-segment elevation myocardial infarction (STEMI) and multi-vessel coronary artery disease. The trial found that preventive PCI of non-infarct arteries with major stenoses significantly reduced the risk of adverse cardiovascular events compared to PCI limited to the infarct artery alone. However, the trial had a small sample size. Guidelines recommend PCI of a non-infarct artery be performed separately from primary PCI, but the optimal timing remains unclear due to varying results from observational studies.
New Treatments in HFrEF
This document summarizes recent clinical trials evaluating new treatments for heart failure with reduced ejection fraction (HFrEF). It finds that sodium-glucose cotransporter-2 inhibitors (SGLT2i) like dapagliflozin and empagliflozin are now foundational therapies for HFrEF as they reduce mortality, hospitalizations, and improve outcomes. Two novel agents, vericiguat and omecamtiv mecarbil, are described as well-tolerated therapies that may provide additional benefit by reducing residual risk in select HFrEF patients. Vericiguat is now FDA-approved and recommended by guidelines for recent worsening HF, while omecamtiv me
Device therapy in heart failure
This document summarizes key information about device therapy in heart failure, including implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT). It discusses major clinical trials that have evaluated the benefits of these devices for primary and secondary prevention of sudden cardiac death. Factors influencing the benefits of ICD therapy are summarized, as well as predictors of mortality after ICD implantation. Complications related to ICDs and CRT devices are also briefly outlined.
Ischemia Trial
The document reports on a study from the ISCHEMIA trial investigating the impact of complete versus incomplete revascularization on clinical outcomes in patients with stable ischemic heart disease treated with an invasive versus conservative strategy. It finds that among patients treated with an invasive strategy, complete anatomic or functional revascularization was associated with improved outcomes compared to incomplete revascularization. However, after adjustment for covariates, the differences in outcomes between complete and incomplete revascularization were no longer statistically significant.
Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction REV...
This study compared percutaneous coronary intervention (PCI) plus optimal medical therapy to optimal medical therapy alone in patients with severe left ventricular systolic dysfunction. Patients were randomly assigned to receive either PCI plus medical therapy or medical therapy alone. The primary outcome was death from any cause or hospitalization for heart failure. At 12 months, PCI did not result in a lower rate of the primary outcome compared to medical therapy alone. Extensive medical therapy was optimized for heart failure in both groups.
hemodynamic in cath lab: aortic stenosis and hocm
1) Cardiac catheterization can provide key information about aortic stenosis including transvalvular pressure gradients, the level of stenosis, and estimation of valve area.
2) Low-flow, low-gradient aortic stenosis can be further classified as either having a decreased ejection fraction or a paradoxically normal ejection fraction.
3) In hypertrophic cardiomyopathy, cardiac catheterization can identify dynamic intraventricular pressure gradients that may only be provoked with maneuvers like the Valsalva maneuver.
Chronic coronary syndromes
1. Chronic coronary syndromes (CCS) refer to conditions involving atherosclerotic plaque buildup in the coronary arteries that can cause various clinical presentations depending on the dynamic nature of the disease process.
2. The most common clinical scenarios in patients with suspected or established CCS involve those with stable angina symptoms, new onset of heart failure, recent acute coronary syndrome, or asymptomatic patients more than 1 year after initial diagnosis or revascularization.
3. Evaluation and management of patients with suspected CCS involves assessing symptoms, risk factors and comorbidities, performing basic testing, estimating pre-test probability of CAD, selecting appropriate non-invasive testing to confirm diagnosis when needed, calculating risk, and determining long-
Stopdapt 2 randomized clinical trial
the 1-year cumulative incidence of a composite end point consisting of cardiovascular death, myocardial infarction, ischemic or hemorrhagic stroke, definite stent thrombosis, and major bleeding was 2.4% in the 1-month DAPT group and 3.7% in the 12-month DAPT group, a difference that met the noninferiority margin of a hazard ratio of 0.5, as well as superiority.
Recommended
PRAMI clinical trial (for STEMI intervention)
The PRAMI trial was a randomized controlled trial that compared preventive percutaneous coronary intervention (PCI) to PCI limited to the infarct artery in patients with ST-segment elevation myocardial infarction (STEMI) and multi-vessel coronary artery disease. The trial found that preventive PCI of non-infarct arteries with major stenoses significantly reduced the risk of adverse cardiovascular events compared to PCI limited to the infarct artery alone. However, the trial had a small sample size. Guidelines recommend PCI of a non-infarct artery be performed separately from primary PCI, but the optimal timing remains unclear due to varying results from observational studies.
New Treatments in HFrEF
This document summarizes recent clinical trials evaluating new treatments for heart failure with reduced ejection fraction (HFrEF). It finds that sodium-glucose cotransporter-2 inhibitors (SGLT2i) like dapagliflozin and empagliflozin are now foundational therapies for HFrEF as they reduce mortality, hospitalizations, and improve outcomes. Two novel agents, vericiguat and omecamtiv mecarbil, are described as well-tolerated therapies that may provide additional benefit by reducing residual risk in select HFrEF patients. Vericiguat is now FDA-approved and recommended by guidelines for recent worsening HF, while omecamtiv me
Device therapy in heart failure
This document summarizes key information about device therapy in heart failure, including implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT). It discusses major clinical trials that have evaluated the benefits of these devices for primary and secondary prevention of sudden cardiac death. Factors influencing the benefits of ICD therapy are summarized, as well as predictors of mortality after ICD implantation. Complications related to ICDs and CRT devices are also briefly outlined.
Ischemia Trial
The document reports on a study from the ISCHEMIA trial investigating the impact of complete versus incomplete revascularization on clinical outcomes in patients with stable ischemic heart disease treated with an invasive versus conservative strategy. It finds that among patients treated with an invasive strategy, complete anatomic or functional revascularization was associated with improved outcomes compared to incomplete revascularization. However, after adjustment for covariates, the differences in outcomes between complete and incomplete revascularization were no longer statistically significant.
Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction REV...
This study compared percutaneous coronary intervention (PCI) plus optimal medical therapy to optimal medical therapy alone in patients with severe left ventricular systolic dysfunction. Patients were randomly assigned to receive either PCI plus medical therapy or medical therapy alone. The primary outcome was death from any cause or hospitalization for heart failure. At 12 months, PCI did not result in a lower rate of the primary outcome compared to medical therapy alone. Extensive medical therapy was optimized for heart failure in both groups.
hemodynamic in cath lab: aortic stenosis and hocm
1) Cardiac catheterization can provide key information about aortic stenosis including transvalvular pressure gradients, the level of stenosis, and estimation of valve area.
2) Low-flow, low-gradient aortic stenosis can be further classified as either having a decreased ejection fraction or a paradoxically normal ejection fraction.
3) In hypertrophic cardiomyopathy, cardiac catheterization can identify dynamic intraventricular pressure gradients that may only be provoked with maneuvers like the Valsalva maneuver.
Chronic coronary syndromes
1. Chronic coronary syndromes (CCS) refer to conditions involving atherosclerotic plaque buildup in the coronary arteries that can cause various clinical presentations depending on the dynamic nature of the disease process.
2. The most common clinical scenarios in patients with suspected or established CCS involve those with stable angina symptoms, new onset of heart failure, recent acute coronary syndrome, or asymptomatic patients more than 1 year after initial diagnosis or revascularization.
3. Evaluation and management of patients with suspected CCS involves assessing symptoms, risk factors and comorbidities, performing basic testing, estimating pre-test probability of CAD, selecting appropriate non-invasive testing to confirm diagnosis when needed, calculating risk, and determining long-
Stopdapt 2 randomized clinical trial
the 1-year cumulative incidence of a composite end point consisting of cardiovascular death, myocardial infarction, ischemic or hemorrhagic stroke, definite stent thrombosis, and major bleeding was 2.4% in the 1-month DAPT group and 3.7% in the 12-month DAPT group, a difference that met the noninferiority margin of a hazard ratio of 0.5, as well as superiority.
THE EMPEROR-PRESERVED TRIAL ppt.pptx
The EMPEROR-Preserved trial evaluated whether empagliflozin reduces cardiovascular death or hospitalization for heart failure in adults with either heart failure with mid-range or preserved ejection fraction. The trial randomized over 5,000 patients to empagliflozin 10 mg daily or placebo, with a median follow up of 26 months. Empagliflozin reduced the primary composite outcome of cardiovascular death or hospitalization for heart failure by 21% compared to placebo, driven mainly by a 29% lower risk of hospitalization for heart failure.
TRILUMINATE Pivotal Trial
La Dra. Belén Álvarez Álvarez comenta los resultados del estudio presentado en ACC Congress 2023, celebrado en New Orleans.
Coronary revascularization in diabetes mellitus and multivessel cad
This document summarizes the FREEDOM trial which compared coronary artery bypass grafting (CABG) to percutaneous coronary intervention (PCI) with drug-eluting stents in 1900 patients with diabetes and multivessel coronary artery disease. The primary outcome of death, heart attack, or stroke occurred in fewer patients treated with CABG compared to PCI over 5 years. CABG was also associated with less need for repeat procedures compared to PCI. However, CABG was linked to more bleeding and acute kidney injury within 30 days. The trial provides evidence that CABG may have longer-term benefits over PCI for patients with diabetes and multiple blocked heart arteries, but also carries higher early risks.
Heart failure with preserved ejection fraction
This document provides an overview of heart failure with preserved ejection fraction (HFpEF). It defines HFpEF as heart failure with an ejection fraction above 40-50%. The document discusses the epidemiology, etiology, pathophysiology, diagnosis and treatment of HFpEF. Key points include that HFpEF is more common in older women and is associated with hypertension, obesity and diabetes. The main mechanism is diastolic dysfunction leading to impaired relaxation and increased stiffness of the left ventricle.
Beta blockers for heart failure
Beta blockers are the most effective therapy for heart failure according to clinical trials. Long term use of beta blockers such as bisoprolol, carvedilol, and sustained release metoprolol succinate can reduce mortality, heart failure hospitalizations, and improve ejection fraction and symptoms of heart failure. While initiation requires slow uptitration, discontinuation of beta blockers during heart failure hospitalization is generally not necessary and may worsen outcomes.
Spontaneous coronary artery dissection
SCAD is a rare, sometimes fatal, traumatic condition with approximately eighty percent of cases affecting women. The coronary artery can suddenly develop a tear, causing blood to flow between the layers which forces them apart, potentially causing a blockage of blood flow through the artery and a resulting heart attack. The condition may be related to female hormone levels, as it is often seen in post-partum women, or in women during or very near menstruation, but not always. It is not uncommon for SCAD to occur in people in good physical shape and with no known prior history of heart related illness. It is also not uncommon for SCAD to occur in people in their 20's, 30's, and 40's, as well as older.
Stitch trial
The STITCH trial evaluated the effect of CABG plus optimal medical therapy (OMT) versus OMT alone on mortality in patients with left ventricular dysfunction and coronary artery disease. A sub-study examined the role of assessing myocardial viability to identify patients who benefit most from CABG. Of 601 patients who underwent viability testing, 487 had viable myocardium and 114 did not. There was no significant interaction between viability status and treatment assignment on mortality or other outcomes. Assessing viability did not identify patients with differential survival benefit from CABG versus OMT alone.
Pci vs cabg
This document discusses PCI (percutaneous coronary intervention) versus CABG (coronary artery bypass grafting) for treating stable coronary artery disease. It provides historical context on the evolution of both procedures and summarizes key randomized controlled trials comparing outcomes of PCI versus CABG. The trials show that CABG provided better long-term outcomes than balloon angioplasty or bare metal stents in multivessel disease. Later trials with drug-eluting stents still found CABG superior for left main or multivessel disease, though the differences were smaller. CABG remains the standard of care for more complex anatomies while PCI is preferred for simpler cases.
Prami trial
A randomized study assigned 465 patients undergoing emergency PCI for acute STEMI to either preventive PCI of stenoses in non-infarct arteries or PCI of the infarct artery only. At a mean follow up of 23 months, the preventive PCI group had lower rates of the primary composite outcome of death from cardiac causes, non-fatal heart attack, or refractory angina (9% vs 23%). Preventive PCI also reduced the risk of subsequent cardiovascular events within the first 6 months after the procedure. Procedure times and contrast usage were increased with preventive PCI, but complication rates were similar between the groups.
DELIVER delivered 2022.pptx
#flozins
🫀DAPA 🆚placebo in HFpEF
Now we have a positive trial!
⬇️18% in CV☠️ death or
worsening HF among LVEF>40%
⬇️ 21%heart failure
💥Results same for LVEF> 60% 🆚LVEF<60%
Beta blockers in Acute MI
This document discusses beta blockers for acute myocardial infarction (AMI). It provides an overview of their mechanism of benefit in AMI, indications and recommendations, and evidence supporting their use. The evidence shows beta blockers reduce infarct size, mortality, and arrhythmias when started early after AMI. Intravenous initiation is generally not recommended for fibrinolytic-treated patients, but oral initiation within 24 hours is. Long-term beta blocker therapy for up to 3 years is also indicated to reduce mortality post-AMI.
LANDMARK TRIALS IN STABLE CAD
The document discusses various clinical trials related to cardiovascular diseases. It summarizes the ACCORD BP study which found that targeting a SBP of <120 mm Hg compared to <140 mm Hg in patients with type 2 diabetes did not reduce cardiovascular events. It also summarizes the HOPE trial which found that ramipril reduced cardiovascular deaths, myocardial infarction, and stroke in high-risk patients without low ejection fraction or heart failure. Finally, it summarizes the EUROPA trial which found that perindopril reduced the primary endpoint of cardiovascular mortality, non-fatal MI, and cardiac arrest in patients with stable coronary artery disease.
Ischemia trial
COMPARES OPTIMAL MEDICAL THERAPY WITH INVASIVE THERAPY IN A PATIENT WITH STABLE ISCHEMIC HEART DISEASE WITH MODERATE TO SEVERE MYOCARDIAL ISCHEMIA ON NON INVASIVE STRESS TESTING
Role of Statin in Secondary Prevention of ACS
dr. Dasdo Antonius Sinaga, SpJP, FIHA. 3rd Pekanbaru Cardiology Update, August 25th 2013. Pangeran Hotel Pekanbaru. Learn more at PerkiPekanbaru.com
EMPULSE Trial
La Dra. Elisabete Alzola Martínez de Antoñana comenta los resultados del estudio publicado en AHA Scientific Sessions 2021.
VICTORIA Trial
El ensayo clínico VICTORIA evaluó la eficacia y seguridad del vericiguat, un activador soluble de guanilato ciclasa, en pacientes con insuficiencia cardiaca y fracción de eyección reducida. Los resultados mostraron que el vericiguat redujo significativamente el objetivo primario combinado de muerte cardiovascular y hospitalizaciones por insuficiencia cardiaca en comparación con el placebo. Aunque no hubo una reducción estadísticamente significativa en la mortalidad cardiovascular, sí se observó una tendencia muy significativa. El tratamiento con ver
Transition study and Pioneer HF study
This document summarizes several studies related to sacubitril/valsartan (LCZ696):
- The TRANSITION trial found that initiating sacubitril/valsartan in hospital shortly after stabilization from acute heart failure had similar safety outcomes as initiating post-discharge. About 50% of patients achieved the top dose within 10 weeks.
- The PIONEER-HF trial showed that among patients hospitalized for acute heart failure, sacubitril/valsartan led to a greater reduction in NT-proBNP levels at 8 weeks compared to enalapril, with similar rates of adverse events.
- The landmark PARADIGM-HF trial demonstrated that sacubitril
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elev...
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction by Dr. Vaibhav Yawalkar MD, DM Cardiology
Reversing cardiac remodeling with HFtreatment
1. This document summarizes research on reversing cardiac remodeling through heart failure treatment. It discusses what remodeling is, the history of the term in medical literature, and types of remodeling (pathological vs physiological).
2. Studies show treatments that lead to "reverse remodeling" like sacubitril/valsartan improve outcomes for heart failure patients. Trials like PARADIGM-HF and PROVE-HF found sacubitril/valsartan reduced biomarkers and improved ejection fraction, indicating reverse remodeling.
3. Subgroup analyses in PROVE-HF found consistent reverse remodeling effects in newly diagnosed and ACE-ARB naive patients as well as those not reaching target sacubitril/vals
Primary Percutaneus coronary intervention
Primary PCI involves performing urgent angioplasty and potentially stenting of the culprit artery in STEMI patients, with the goal of reopening the blocked vessel within 90 minutes of first medical contact. It is the preferred reperfusion strategy when it can be performed promptly by an experienced team. Factors such as patient age, time to treatment, comorbidities, and initial flow in the artery help determine whether primary PCI or thrombolysis is most appropriate. Optimal anticoagulation and antiplatelet regimens along with adjunctive therapies like manual thrombectomy can improve outcomes of primary PCI.
Hazte socio de la Sociedad Española de Cardiología
La Sociedad Española de Cardiología (SEC) es una organización científica sin ánimo de lucro con la misión de reducir el impacto adverso de las enfermedades cardiovasculares y promover una mejor salud cardiovascular en la ciudadanía.
Identificación del paciente con alto riesgo tras SCA reciente
Ponencia presentada por la Dra. Marisol Bravo Amaro en el CardioTV Live ‘Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome coronario agudo reciente’, realizado el 21 de mayo de 2024 en la Casa del Corazón
More Related Content
What's hot
THE EMPEROR-PRESERVED TRIAL ppt.pptx
The EMPEROR-Preserved trial evaluated whether empagliflozin reduces cardiovascular death or hospitalization for heart failure in adults with either heart failure with mid-range or preserved ejection fraction. The trial randomized over 5,000 patients to empagliflozin 10 mg daily or placebo, with a median follow up of 26 months. Empagliflozin reduced the primary composite outcome of cardiovascular death or hospitalization for heart failure by 21% compared to placebo, driven mainly by a 29% lower risk of hospitalization for heart failure.
TRILUMINATE Pivotal Trial
La Dra. Belén Álvarez Álvarez comenta los resultados del estudio presentado en ACC Congress 2023, celebrado en New Orleans.
Coronary revascularization in diabetes mellitus and multivessel cad
This document summarizes the FREEDOM trial which compared coronary artery bypass grafting (CABG) to percutaneous coronary intervention (PCI) with drug-eluting stents in 1900 patients with diabetes and multivessel coronary artery disease. The primary outcome of death, heart attack, or stroke occurred in fewer patients treated with CABG compared to PCI over 5 years. CABG was also associated with less need for repeat procedures compared to PCI. However, CABG was linked to more bleeding and acute kidney injury within 30 days. The trial provides evidence that CABG may have longer-term benefits over PCI for patients with diabetes and multiple blocked heart arteries, but also carries higher early risks.
Heart failure with preserved ejection fraction
This document provides an overview of heart failure with preserved ejection fraction (HFpEF). It defines HFpEF as heart failure with an ejection fraction above 40-50%. The document discusses the epidemiology, etiology, pathophysiology, diagnosis and treatment of HFpEF. Key points include that HFpEF is more common in older women and is associated with hypertension, obesity and diabetes. The main mechanism is diastolic dysfunction leading to impaired relaxation and increased stiffness of the left ventricle.
Beta blockers for heart failure
Beta blockers are the most effective therapy for heart failure according to clinical trials. Long term use of beta blockers such as bisoprolol, carvedilol, and sustained release metoprolol succinate can reduce mortality, heart failure hospitalizations, and improve ejection fraction and symptoms of heart failure. While initiation requires slow uptitration, discontinuation of beta blockers during heart failure hospitalization is generally not necessary and may worsen outcomes.
Spontaneous coronary artery dissection
SCAD is a rare, sometimes fatal, traumatic condition with approximately eighty percent of cases affecting women. The coronary artery can suddenly develop a tear, causing blood to flow between the layers which forces them apart, potentially causing a blockage of blood flow through the artery and a resulting heart attack. The condition may be related to female hormone levels, as it is often seen in post-partum women, or in women during or very near menstruation, but not always. It is not uncommon for SCAD to occur in people in good physical shape and with no known prior history of heart related illness. It is also not uncommon for SCAD to occur in people in their 20's, 30's, and 40's, as well as older.
Stitch trial
The STITCH trial evaluated the effect of CABG plus optimal medical therapy (OMT) versus OMT alone on mortality in patients with left ventricular dysfunction and coronary artery disease. A sub-study examined the role of assessing myocardial viability to identify patients who benefit most from CABG. Of 601 patients who underwent viability testing, 487 had viable myocardium and 114 did not. There was no significant interaction between viability status and treatment assignment on mortality or other outcomes. Assessing viability did not identify patients with differential survival benefit from CABG versus OMT alone.
Pci vs cabg
This document discusses PCI (percutaneous coronary intervention) versus CABG (coronary artery bypass grafting) for treating stable coronary artery disease. It provides historical context on the evolution of both procedures and summarizes key randomized controlled trials comparing outcomes of PCI versus CABG. The trials show that CABG provided better long-term outcomes than balloon angioplasty or bare metal stents in multivessel disease. Later trials with drug-eluting stents still found CABG superior for left main or multivessel disease, though the differences were smaller. CABG remains the standard of care for more complex anatomies while PCI is preferred for simpler cases.
Prami trial
A randomized study assigned 465 patients undergoing emergency PCI for acute STEMI to either preventive PCI of stenoses in non-infarct arteries or PCI of the infarct artery only. At a mean follow up of 23 months, the preventive PCI group had lower rates of the primary composite outcome of death from cardiac causes, non-fatal heart attack, or refractory angina (9% vs 23%). Preventive PCI also reduced the risk of subsequent cardiovascular events within the first 6 months after the procedure. Procedure times and contrast usage were increased with preventive PCI, but complication rates were similar between the groups.
DELIVER delivered 2022.pptx
#flozins
🫀DAPA 🆚placebo in HFpEF
Now we have a positive trial!
⬇️18% in CV☠️ death or
worsening HF among LVEF>40%
⬇️ 21%heart failure
💥Results same for LVEF> 60% 🆚LVEF<60%
Beta blockers in Acute MI
This document discusses beta blockers for acute myocardial infarction (AMI). It provides an overview of their mechanism of benefit in AMI, indications and recommendations, and evidence supporting their use. The evidence shows beta blockers reduce infarct size, mortality, and arrhythmias when started early after AMI. Intravenous initiation is generally not recommended for fibrinolytic-treated patients, but oral initiation within 24 hours is. Long-term beta blocker therapy for up to 3 years is also indicated to reduce mortality post-AMI.
LANDMARK TRIALS IN STABLE CAD
The document discusses various clinical trials related to cardiovascular diseases. It summarizes the ACCORD BP study which found that targeting a SBP of <120 mm Hg compared to <140 mm Hg in patients with type 2 diabetes did not reduce cardiovascular events. It also summarizes the HOPE trial which found that ramipril reduced cardiovascular deaths, myocardial infarction, and stroke in high-risk patients without low ejection fraction or heart failure. Finally, it summarizes the EUROPA trial which found that perindopril reduced the primary endpoint of cardiovascular mortality, non-fatal MI, and cardiac arrest in patients with stable coronary artery disease.
Ischemia trial
COMPARES OPTIMAL MEDICAL THERAPY WITH INVASIVE THERAPY IN A PATIENT WITH STABLE ISCHEMIC HEART DISEASE WITH MODERATE TO SEVERE MYOCARDIAL ISCHEMIA ON NON INVASIVE STRESS TESTING
Role of Statin in Secondary Prevention of ACS
dr. Dasdo Antonius Sinaga, SpJP, FIHA. 3rd Pekanbaru Cardiology Update, August 25th 2013. Pangeran Hotel Pekanbaru. Learn more at PerkiPekanbaru.com
EMPULSE Trial
La Dra. Elisabete Alzola Martínez de Antoñana comenta los resultados del estudio publicado en AHA Scientific Sessions 2021.
VICTORIA Trial
El ensayo clínico VICTORIA evaluó la eficacia y seguridad del vericiguat, un activador soluble de guanilato ciclasa, en pacientes con insuficiencia cardiaca y fracción de eyección reducida. Los resultados mostraron que el vericiguat redujo significativamente el objetivo primario combinado de muerte cardiovascular y hospitalizaciones por insuficiencia cardiaca en comparación con el placebo. Aunque no hubo una reducción estadísticamente significativa en la mortalidad cardiovascular, sí se observó una tendencia muy significativa. El tratamiento con ver
Transition study and Pioneer HF study
This document summarizes several studies related to sacubitril/valsartan (LCZ696):
- The TRANSITION trial found that initiating sacubitril/valsartan in hospital shortly after stabilization from acute heart failure had similar safety outcomes as initiating post-discharge. About 50% of patients achieved the top dose within 10 weeks.
- The PIONEER-HF trial showed that among patients hospitalized for acute heart failure, sacubitril/valsartan led to a greater reduction in NT-proBNP levels at 8 weeks compared to enalapril, with similar rates of adverse events.
- The landmark PARADIGM-HF trial demonstrated that sacubitril
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elev...
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction by Dr. Vaibhav Yawalkar MD, DM Cardiology
Reversing cardiac remodeling with HFtreatment
1. This document summarizes research on reversing cardiac remodeling through heart failure treatment. It discusses what remodeling is, the history of the term in medical literature, and types of remodeling (pathological vs physiological).
2. Studies show treatments that lead to "reverse remodeling" like sacubitril/valsartan improve outcomes for heart failure patients. Trials like PARADIGM-HF and PROVE-HF found sacubitril/valsartan reduced biomarkers and improved ejection fraction, indicating reverse remodeling.
3. Subgroup analyses in PROVE-HF found consistent reverse remodeling effects in newly diagnosed and ACE-ARB naive patients as well as those not reaching target sacubitril/vals
Primary Percutaneus coronary intervention
Primary PCI involves performing urgent angioplasty and potentially stenting of the culprit artery in STEMI patients, with the goal of reopening the blocked vessel within 90 minutes of first medical contact. It is the preferred reperfusion strategy when it can be performed promptly by an experienced team. Factors such as patient age, time to treatment, comorbidities, and initial flow in the artery help determine whether primary PCI or thrombolysis is most appropriate. Optimal anticoagulation and antiplatelet regimens along with adjunctive therapies like manual thrombectomy can improve outcomes of primary PCI.
What's hot (20)
Coronary revascularization in diabetes mellitus and multivessel cad
Coronary revascularization in diabetes mellitus and multivessel cad
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elev...
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elev...
More from Sociedad Española de Cardiología
Hazte socio de la Sociedad Española de Cardiología
La Sociedad Española de Cardiología (SEC) es una organización científica sin ánimo de lucro con la misión de reducir el impacto adverso de las enfermedades cardiovasculares y promover una mejor salud cardiovascular en la ciudadanía.
Identificación del paciente con alto riesgo tras SCA reciente
Ponencia presentada por la Dra. Marisol Bravo Amaro en el CardioTV Live ‘Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome coronario agudo reciente’, realizado el 21 de mayo de 2024 en la Casa del Corazón
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...Sociedad Española de Cardiología
Ponencia presentada por el Dr. Armando Oterino Manzanas en el CardioTV Live ‘Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome coronario agudo reciente’, realizado el 21 de mayo de 2024 en la Casa del CorazónDebatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...Sociedad Española de Cardiología
Ponencia presentada por la Dra. Miriam Martín Toro en el CardioTV Live ‘Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome coronario agudo reciente’, realizado el 21 de mayo de 2024 en la Casa del CorazónProyecto FARO. Prevención secundaria de la enfermedad cardiovascular ateroscl...
Proyecto FARO. Prevención secundaria de la enfermedad cardiovascular ateroscl...Sociedad Española de Cardiología
Ponencia presentada por los Dres. M.ª Dolores Mesa Rubio, Javier Mora Robles, Margarita Reina Sánchez, M.ª José Castillo Moraga y José Luis Bianchi Llave en el CardioTV Focus, publicado el 25 de abril de 2024 en la Casa del Corazón (Madrid).Estudio IVUS-ACS
La Dra. Neus Salvatella Giralt comenta los resultados del estudio IVUS-ACS, presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio PREVENT
La Dra. Neus Salvatella Giralt comenta los resultados del estudio PREVENT, presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio DEDICATE-DZHK6
La Dra. Neus Salvatella Giralt comenta los resultados del estudio presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio TRAVERSE
La Dra. Júlia Aranyó Llach comenta los resultados del estudio presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio FULL-REVASC
El Dr. Borja Rivero Santana comenta los resultados del estudio FULL-REVASC presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio IMPROVE-HCM
La Dra. Júlia Aranyó Llach comenta los resultados del estudio IMPROVE-HCM, presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio ORBITA-COSMIC
El Dr. Borja Rivero Santana comenta los resultados del estudio ORBITA-COSMIC, presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio ARISE-HF
La Dra. Júlia Aranyó Llach comenta los resultados del estudio ARISE-HF, presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio TACTiC
El Dr. Koldo Ugedo Alzaga comenta los resultados del estudio TACTiC, presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio ULTIMATE DAPT
La Dra. Neus Salvatella Giralt comenta los resultados del estudio presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio SHASTA-2
El Dr. Koldo Ugedo Alzaga comenta los resultados del estudio SHASTA-2 presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio MINT
La Dra. Júlia Aranyó Llach comenta los resultados del estudio MINT presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
ePóster. Reducciones c-LDL el primer año de tratamiento con inclisirán
ePóster. Reducciones c-LDL el primer año de tratamiento con inclisiránSociedad Española de Cardiología
El Dr. Koldo Ugedo Alzaga comenta los resultados del estudio presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).Estudio SMART
La Dra. Neus Salvatella Giralt comenta los resultados del estudio SMART presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio REDUCE-AMI
La Dra. Neus Salvatella Giralt comenta los resultados del estudio REDUCE-AMI presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
More from Sociedad Española de Cardiología (20)
Hazte socio de la Sociedad Española de Cardiología
Hazte socio de la Sociedad Española de Cardiología
Identificación del paciente con alto riesgo tras SCA reciente
Identificación del paciente con alto riesgo tras SCA reciente
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Proyecto FARO. Prevención secundaria de la enfermedad cardiovascular ateroscl...
Proyecto FARO. Prevención secundaria de la enfermedad cardiovascular ateroscl...
ePóster. Reducciones c-LDL el primer año de tratamiento con inclisirán
ePóster. Reducciones c-LDL el primer año de tratamiento con inclisirán
Recently uploaded
Adhd Medication Shortage Uk - trinexpharmacy.com
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Do you have abnormal smell after periods? It may be vaginitis. Do not worry, herbal medicine Fuyan Pill can help you get a cure.
Journal Article Review on Rasamanikya
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Efficacy of Avartana Sneha in Ayurveda
Avartana Sneha is a unique method of Preparation of Sneha Kalpana in Ayurveda, mainly it is indicated for the Vataja rogas.
share - Lions, tigers, AI and health misinformation, oh my!.pptx
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
This document outlines policies and procedures for handling narcotic and controlled drugs in NABH accredited hospitals.
The Nervous and Chemical Regulation of Respiration
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Identifying Major Symptoms of Slip Disc.
Our backs are like superheroes, holding us up and helping us move around. But sometimes, even superheroes can get hurt. That’s where slip discs come in.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.Hiranandani Hospital Powai News [Read Now].pdf
Hiranandani Hospital in Powai, Mumbai, is a premier healthcare institution that has been serving the community with exceptional medical care since its establishment. As a part of the renowned Hiranandani Group, the hospital is committed to delivering world-class healthcare services across a wide range of specialties, including kidney transplantation. With its state-of-the-art facilities, advanced medical technology, and a team of highly skilled healthcare professionals, Hiranandani Hospital has earned a reputation as a trusted name in the healthcare industry. The hospital's patient-centric approach, coupled with its focus on innovation and excellence, ensures that patients receive the highest standard of care in a compassionate and supportive environment.
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Recently uploaded (20)
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
COMPLETE Trial
- 1. Begoña Benito VillabrigaCOMPLETE Trial Begoña Benito VillabrigaGuidelines for the management of dyslipidaemiasCOMPLETE Trial
- 2. Begoña Benito VillabrigaCOMPLETE TrialCOMPLETE Trial
- 3. Begoña Benito VillabrigaCOMPLETE TrialCOMPLETE Trial
- 4. Begoña Benito VillabrigaCOMPLETE Trial 140 centers, 31 countries
- 5. Begoña Benito VillabrigaCOMPLETE TrialCOMPLETE Trial Results: Baseline and procedural characteristics
- 6. Begoña Benito VillabrigaCOMPLETE Trial
- 7. Begoña Benito VillabrigaCOMPLETE Trial
- 8. Begoña Benito VillabrigaCOMPLETE Trial Secondary outcomes Safety
- 9. Begoña Benito VillabrigaCOMPLETE Trial Subgroups
- 10. Begoña Benito VillabrigaCOMPLETE Trial